Novo Nordisk completed the acquisition of a 64.3% stake in Biocorp for $109m.

Novo Nordisk, a Danish drug developer, completed the acquisition of a 64.3% stake in Biocorp, a French medical device designer, for $109m. "We are delighted to join Novo Nordisk, a leading global healthcare company. This combination rewards our efforts, begun 5 years ago, to digitalize the treatment and monitoring of chronic patients, with the constant aim of easing their daily lives. Our teams are enthusiastic about pursuing this public health mission, which will be intensified by the strength of Novo Nordisk's global presence," Eric Dessertenne, Biocorp CEO.